Cencora layoffs, on the record
Every job cut, severance charge and restructuring Cencora reported in its annual reports, 2022 to 2025, quoted from the filings. Headcount went from approximately 44,000 to more than 51,000.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2022 | approximately 44,000 | September 30, 2022 |
| 10-K for 2023 | approximately 46,000 | September 30, 2023 |
| 10-K for 2024 | more than 46,000 | September 30, 2024 |
| 10-K for 2025 | more than 51,000 | September 30, 2025 |
Job cuts, severance and restructuring
Our summaryThe company recorded severance and other restructuring charges in fiscal 2022, mainly an asset write down tied to its office optimization plan.
Word for word“Acquisition, integration, and restructuring expenses in the fiscal year ended September 30, 2022 included $119.6 million of acquisition-related deal and integration costs primarily related to the integration of Alliance Healthcare, $35.5 million of severance and other restructuring initiatives primarily related to the write down of assets in connection with our office optimization plan, and $28.0 million related to our business transformation efforts.” 10-K for 2022
Our summaryThe company recorded severance and other restructuring charges in fiscal 2021, mainly tied to disposing of assets under its office optimization plan.
Word for word“Acquisition, integration, and restructuring expenses in the fiscal year ended September 30, 2021 included $117.0 million of acquisition-related deal and integration costs primarily related to the June 2021 acquisition of Alliance Healthcare, $46.1 million of severance and other restructuring initiatives primarily related to the disposal of assets in connection with our office optimization plan, and $36.3 million related to our business transformation efforts.” 10-K for 2022
Our summaryThe company recorded severance costs in fiscal 2020 mainly for position eliminations after deciding to permanently exit the PharMEDium compounding business.
Word for word“Acquisition, integration, and restructuring expenses in the fiscal year ended September 30, 2020 included $38.0 million related to our business transformation efforts, $34.4 million of severance costs primarily related to position eliminations resulting from our decision to permanently exit the PharMEDium compounding business, and $12.6 million of acquisition-related deal and integration costs and other restructuring initiatives.” 10-K for 2022
Our summaryThe company incurred employee severance costs in fiscal 2022 for restructuring in certain U.S. Healthcare Solutions businesses.
Word for word“Employee severance in the fiscal year ended September 30, 2022 included costs primarily related to restructuring activities within certain businesses in the U.S. Healthcare Solutions reportable segment.” 10-K for 2022
Our summaryThe company incurred employee severance costs in fiscal 2021 for restructuring mainly within one International Healthcare Solutions business unit.
Word for word“Employee severance in the fiscal year ended September 30, 2021 included costs primarily related to restructuring activities primarily within one business unit in the International Healthcare Solutions reportable segment.” 10-K for 2022
Our summaryThe company recorded restructuring and employee severance costs in fiscal 2023, mainly for workforce reductions in both of its reportable segments.
Word for word“Restructuring and employee severance costs in the fiscal year ended September 30, 2023 primarily included expenses incurred in connection with workforce reductions in both of our reportable segments.” 10-K for 2023
Our summaryThe company recorded restructuring costs in fiscal 2022, mainly asset write-downs from its office optimization plan and restructuring in certain U.S. Healthcare Solutions businesses.
Word for word“Restructuring and employee severance costs in the fiscal year ended September 30, 2022 included costs primarily related to the write down of assets related to our office optimization plan and restructuring activities within certain businesses in the U.S. Healthcare Solutions reportable segment.” 10-K for 2023
Our summaryCencora recorded restructuring and severance costs in fiscal 2024, mainly for facility closures under its office optimization plan and workforce reductions in both reportable segments.
Word for word“Restructuring and employee severance costs in fiscal 2024 primarily included expenses incurred related to facility closures in connection with our office optimization plan and workforce reductions in both of our reportable segments.” 10-K for 2024
Our summaryCencora recorded restructuring and severance costs in fiscal 2023, mainly for workforce reductions in both reportable segments.
Word for word“Restructuring and employee severance costs in fiscal 2023 primarily included expenses incurred in connection with workforce reductions in both of our reportable segments.” 10-K for 2024
Our summaryCencora recorded restructuring costs in fiscal 2022 tied to asset write-downs for its office optimization plan and restructuring within certain U.S. Healthcare Solutions businesses.
Word for word“Restructuring and employee severance costs in fiscal 2022 included costs primarily related to the write down of assets with respect to the Company's office optimization plan and restructuring activities within certain businesses in the U.S. Healthcare Solutions reportable segment.” 10-K for 2024
Our summaryIn fiscal 2025 the company recorded restructuring and severance costs, mainly for workforce reductions in both of its reportable segments.
Word for word“Restructuring and employee severance costs in fiscal 2025 primarily included expenses incurred related to workforce reductions in both of the Company’s reportable segments.” 10-K for 2025
Our summaryIn fiscal 2024 the company recorded restructuring and severance costs, mainly for facility closures under its office optimization plan and workforce reductions in both segments.
Word for word“Restructuring and employee severance costs in fiscal 2024 primarily included expenses incurred related to facility closures in connection with the Company’s office optimization plan and workforce reductions in both of its reportable segments.” 10-K for 2025
Our summaryIn fiscal 2023 the company recorded restructuring and severance costs, mainly for workforce reductions in both of its reportable segments.
Word for word“Restructuring and employee severance costs in fiscal 2023 primarily included expenses incurred in connection with workforce reductions in both of the Company’s reportable segments.” 10-K for 2025
| Fiscal year ended | Severance costs | Restructuring charges |
|---|---|---|
| 2016-09-30 | $38.8 million | $102.9 million |
| 2017-09-30 | $7.8 million | $959.3 million |
| 2018-09-30 | $36.7 million | $183.5 million |
| 2019-09-30 | $34.1 million | $330.5 million |
| 2020-09-30 | $34.4 million | $6.81 billion |
| 2021-09-30 | $46.1 million | $82.3 million |
| 2022-09-30 | $35.3 million | $63.5 million |
| 2023-09-30 | $105.2 million | $229.9 million |
| 2024-09-30 | $70 million | $233.6 million |
| 2025-09-30 | $101.6 million | $229.4 million |
Cencora filed 1 restructuring notice (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Cencora’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2025-11-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.